Wisconsin said a “binding two-year NIL agreement” was violated and that the school has “credible information indicating ...
VisiRose Inc. ('VisiRose' or the 'Company'), a privately-held, clinical-stage biotechnology company developing novel ocular ...
KNOXVILLE, Tenn., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced a $3 million seed financing round for VisiRose, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback